Jaguar Animal Health, Inc. JAGX

Jaguar Health stock surged after crofelemer progress in ultra-rare pediatric intestinal diseases, notably microvillus inclusion disease (MVID). The shares jumped about 32% to $9.32 on light volume, aided by a razor-thin post-split float of 342,780 shares that can magnify moves. Crofelemer’s NDA path targets Q2 2027, with data showing up to a 48% reduction in parenteral support in pediatric MVID when used as an adjunct. The company is pursuing Breakthrough Therapy Designation and has secured FDA user-fee waivers, reducing upfront costs. Jaguar also launched Neonorm Dog on Amazon, expanding non-prescription offerings. Dilution risk remains as Jaguar funds the clinical path through ongoing capital raises amid net losses, and a regulatory setback on the MVID filing or further financing could reverse gains. Rare-disease pipeline advancement amid a tiny float could meaningfully shift valuation and investor sentiment, albeit contingent on successful financing and FDA outcomes.

Jaguar Health stock surged premarket after a 1-for-15 reverse split to satisfy Nasdaq requirements, marking its best session in more than eight years. FDA waivers for fiscal 2027 program fees canceled for Mytesi and Canalevia-CA1—products marketed by Future Pak under a licensing deal—reduce costs on these two programs. The company is pursuing a mid-2027 NDA for Crofelemer-based microvillus inclusion disease (MVID) and short bowel syndrome, with all randomized children in the MVID trial continuing into a single-blind extension; some patients showed reduced IV nutrition needs after Crofelemer. Jaguar remains focused on rare-disease GI, while licensing revenue contributed modestly to Q2 results and losses widened. Management promotes the rare-disease strategy amid strong retail interest on StockTwits, signaling potential upside. Waivers, NDA timing, and a licensing deal create a meaningful strategic pivot with potential to alter growth trajectory.

Jaguar Health, Inc., through its Napo Pharmaceuticals unit, announced FDA fee waivers for 2027 for crofelemer products Mytesi delayed-release tablets and the canine Canalevia-CA1. The waivers cover PDUFA fees for Mytesi and a Center for Veterinary Medicine fee for Canalevia-CA1 as the company advances its rare disease intestinal failure program targeting microvillus inclusion disease (MVID) and short bowel syndrome with crofelemer powder for oral solution. Jaguar plans to file a New Drug Application for crofelemer for MVID in mid-2027. Mytesi is FDA-approved for noninfectious diarrhea in adults with HIV/AIDS on ART and is marketed in the U.S. by Future Pak, while Canalevia-CA1 is conditionally approved for chemotherapy-induced diarrhea in dogs. The release reiterates forward-looking statements about development timelines and potential risks. Regulatory fee waivers reduce upfront costs and support the planned mid-2027 NDA filing for MVID crofelemer.

All randomized pediatric patients continue in the single-blind extension phase of Jaguar Health's pivotal crofelemer trial for microvillus inclusion disease with intestinal failure. Trial extension phase continuation advances crofelemer development for rare disease indication.

Jaguar Health Inc reported Q2 2026 earnings call highlights focused on rare disease breakthroughs. Rare disease breakthroughs represent major strategic progress likely to shift company trajectory and investor sentiment.

Jaguar Health reports positive consumer and veterinary market research findings supporting commercial opportunity for Neonorm Dog. Positive market research findings indicate commercial potential for Neonorm Dog product.

Jaguar Health presented groundbreaking results at ESPGHAN 2026 showing crofelemer as effective adjunctive oral therapy for pediatric intestinal failure. Positive clinical data on new crofelemer use may raise investor interest without guaranteeing near-term revenue or approvals.

Jaguar Health completes submission of New Animal Drug Application for full FDA approval of Crofelemer to treat chemotherapy-induced diarrhea in dogs. Completion of FDA submission advances regulatory path for new veterinary product approval with direct potential to expand Jaguar Health revenue streams.

Jaguar Health announces plan to explore strategic alternatives aligned with targeted NDA filing for rare disease intestinal failure program. NDA filing pursuit plus strategic alternatives review marks major regulatory and directional shift with strong potential to reshape company trajectory.

Jaguar Health advances crofelemer development for genetically defined rare congenital GI disorders through ethnobotanical medicine research. R&D progress on crofelemer expands potential applications in niche GI disorders without immediate commercial or regulatory milestones.

Jaguar Health Inc reported a revenue surge during its Q1 2026 earnings call alongside strategic updates. Revenue surge signals improved financial results with potential to lift valuation and market position.

Jaguar Health (JAGX) held its Q3 2025 earnings call covering financial results, operational updates, and management outlook on company performance and strategy. Q3 earnings details and forward guidance directly shape near-term stock valuation and investor sentiment for JAGX.

Jaguar Animal Health (JAGX) released its Q4 2025 earnings transcript covering financial results, operational updates, and forward guidance for the animal health business. Q4 2025 earnings data and management outlook can drive major shifts in JAGX valuation and investor positioning.

Jaguar Health reported first quarter 2026 financial results with details on revenue, net loss, operating expenses, and updates to its animal health product pipeline and commercialization efforts. Quarterly financial disclosures provide performance metrics that can temporarily shift investor sentiment and stock valuation.

Jaguar Health continues active treatment only in its pivotal multicenter clinical trial for pediatric patients with Microvillus Inclusion Disease to support NDA for liquid oral crofelemer. Trial continuation toward NDA for crofelemer in rare pediatric disease may drive major revenue potential and shift company trajectory.

Jaguar Animal Health, Inc. (JAGX) regained compliance with Nasdaq's minimum 1.1 million publicly held shares requirement and received a 180-day extension until May 18, 2026, to meet the $1 minimum bid price rule. Regaining share compliance and securing a bid price extension averts immediate delisting risk, boosting investor sentiment and supporting market performance.

Jaguar Health announces preliminary discussions with the FDA to evaluate Breakthrough Therapy Designation for crofelemer in treating Microvillus Inclusion Disease (MVID). Preliminary FDA discussions for Breakthrough Therapy Designation could accelerate crofelemer development for rare MVID, significantly boosting JAGX's regulatory prospects and investor sentiment.

Jaguar Health launches Neonorm Dog, expanding its Neonorm franchise to address gut health in companion animals. New product launch into companion animal gut health expands franchise and targets growing market segment for revenue growth.

Jaguar Health announced statistically significant results from an effectiveness trial of Crofelemer (FDA-approved Canalevia-CA1) for treating chemotherapy-induced diarrhea in dogs. Positive trial results for an FDA-approved drug in a new canine indication could significantly boost revenue potential and market sentiment.

Jaguar Animal Health, Inc. (JAGX) received a Nasdaq extension until May 15, 2026, to regain compliance with the minimum bid price listing rule and announced plans for a reverse stock split. Nasdaq compliance extension averts immediate delisting but reverse stock split signals financial distress and pressures share price.

Jaguar Health announces acceptance of two late-breaking abstracts for liquid oral crofelemer treatment of intestinal failure in pediatric patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN). Acceptance of late-breaking abstracts at ESPGHAN validates clinical progress in pediatric crofelemer, potentially expanding market opportunities and enhancing investor sentiment.

Jaguar Animal Health, Inc. (JAGX) reports approval of all proposals at its April 2026 Special Meeting of Stockholders. Full stockholder approval at a special meeting provides moderate boost to governance stability and investor confidence without indicating transformative changes.

Jaguar Health Inc (JAGX) Q4 2025 earnings call highlights revenue growth and strategic advancements. Revenue growth and strategic initiatives signal major positive shifts in financial performance and market positioning for JAGX.

Jaguar Health completed an effectiveness trial supporting FDA-approved crofelemer for treating chemotherapy-induced diarrhea (CID) in dogs. Trial completion strengthens evidence for crofelemer's use in CID treatment, positioning JAGX for expanded veterinary market revenue and positive investor sentiment.

Jaguar Animal Health, Inc. (JAGX) reported its 2025 financial results. Financial results disclosure significantly influences stock valuation and investor confidence.

FDA feedback supports extension phase of Jaguar Health's clinical trial for crofelemer in treating Microvillus Inclusion Disease (MVID). FDA's positive feedback enables crofelemer trial extension for rare disease MVID, advancing JAGX's pipeline and potentially driving significant investor sentiment.

Jaguar Animal Health, Inc. (JAGX) strengthened its balance sheet by restructuring and reducing royalty and debt obligations while extinguishing warrants. Restructuring debt, royalties, and extinguishing warrants reduces financial burdens and improves liquidity, significantly boosting future stability and investor confidence.

Jaguar Animal Health, Inc. (JAGX) secured an additional $3 million payment from Future Pak for its human product Mytesi and veterinary product Canalevia-CA1. Securing $3 million in non-dilutive funding bolsters cash position and supports operational runway for a microcap biotech.

Jaguar Animal Health, Inc. (JAGX) announces a special one-time stock dividend to existing shareholders. A special one-time stock dividend boosts short-term market sentiment and liquidity without impacting core financials.

Jaguar Animal Health, Inc. (JAGX) has emphasized its strategic focus on rare intestinal failure diseases, bolstered by non-dilutive funding from a recent licensing agreement for its product Mytesi. This deal is expected to enhance the company's financial position and support its initiatives in addressing these specialized medical conditions. The licensing deal for Mytesi represents a significant strategic move that could enhance Jaguar's market position and financial outlook.